...
首页> 外文期刊>BMC Nephrology >Dysglycemia but not lipids is associated with abnormal urinary albumin excretion in diabetic kidney disease: a report from the Kidney Early Evaluation Program (KEEP)
【24h】

Dysglycemia but not lipids is associated with abnormal urinary albumin excretion in diabetic kidney disease: a report from the Kidney Early Evaluation Program (KEEP)

机译:糖尿病肾脏疾病中的血糖异常,而非血脂异常与尿白蛋白排泄异常有关:肾脏早期评估计划(KEEP)的报告

获取原文

摘要

Background The relationship between glycemic control and lipid abnormalities with urinary albumin-creatinine ratio (ACR) in chronic kidney disease (CKD) patients with diabetes mellitus (DM) is unknown. We sought to investigate the association of dyslipidemia and glycemic control with levels of albuminuria in the National Kidney Foundation (NKF) Kidney Early Evaluation Program (KEEP) participants with DM and CKD stage 3 or higher. Methods We performed a cross-sectional study of 6639 eligible KEEP patients with DM and CKD Stage 3 to 5 from June 2008 to December 2009. Multivariate logistic regression was used to evaluate the association of lipid parameters (per 10 mg/dl change in serum level) and glycosylated hemoglobin (HbA1c) values with three degrees of albuminuria normo (300 mg?g). Results 2141 KEEP participants were included. HbA1c levels were strongly associated with micro-albuminuria (compared to normo-albuminuria) and macro-albuminuria (compared to normo-albuminuria and micro-albuminuria). Each 1.0% increase in HbA1c increased the odds of micro-albuminuria by 32% (OR 1.32, 95% CI 1.23-1.42) and the odds of macro-albuminuria (vs. microalbuminuria) by 16% (OR 1.16, 95% CI 1.05-1.28). Only increases in serum HDL were associated with decreased odds of micro-albuminuria; otherwise, the association between other components of the serum lipid profile with urinary ACR did not reach statistical significance. Conclusion In this cross-sectional study of 2141 KEEP participants with DM and CKD stages 3–5, overall glycemic control but not lipids were associated with abnormal urinary albumin excretion, a marker of increased risk for progressive disease.
机译:背景技术慢性肾脏病(DM)糖尿病患者(DM)的血糖控制与血脂异常与尿白蛋白-肌酐比(ACR)之间的关系尚不清楚。我们试图在美国国家肾脏基金会(NKF)肾脏早期评估计划(KEEP)患有DM和CKD 3级或更高水平的参与者中研究血脂异常和血糖控制与蛋白尿水平的关系。方法我们从2008年6月至2009年12月对6639名符合条件的KEEP DM和CKD第3至5期患者进行了横断面研究。多因素logistic回归用于评估血脂参数(每10 mg / dl血清水平变化)的相关性)和糖蛋白化血红蛋白(HbA1c)值,以及三度蛋白尿正常(300 mg?g)。结果包括2141名KEEP参与者。 HbA1c水平与微量白蛋白尿(相对于正常白蛋白尿)和大量白蛋白尿(相对于正常白蛋白尿和微量白蛋白尿)密切相关。 HbA1c每增加1.0%,微量蛋白尿的几率增加32%(OR 1.32,95%CI 1.23-1.42),而微量蛋白尿的几率(相对于微量蛋白尿)增加16%(OR 1.16,95%CI 1.05) -1.28)。血清HDL升高仅与微量白蛋白尿几率降低有关;否则,血脂谱的其他成分与尿液ACR之间的关联没有统计学意义。结论在这项对2141名KEEP参与者处于DM和CKD 3-5期的横断面研究中,总体血糖控制而非脂质与尿白蛋白排泄异常相关,尿白蛋白排泄是进行性疾病风险增加的标志。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号